Stock Track | WUXI XDC Soars 7.37% on Positive Analyst Coverage Initiation-To The Moon - Tiger Brokers Online Investing Community

Like
Comment
Favorite

Stock Track | WUXI XDC Soars 7.37% on Positive Analyst Coverage Initiation

Stock Track2024-11-27

WUXI XDC, a leading biopharmaceutical company, saw its stock price surge 7.37% in intraday trading on Wednesday. The rally was driven by a bullish initiation of coverage from SPDB International HK.

In a research note published on Wednesday afternoon, SPDB International HK analysts initiated coverage on WUXI XDC with a "Buy" rating and set a price target of HK$35 for the stock. The favorable outlook and positive rating triggered increased buying interest, propelling WUXI XDC's shares higher during the trading session.

The surge in WUXI XDC's stock price highlights the market's reaction to the optimistic analyst coverage, underscoring investor confidence in the company's prospects and growth potential within the biopharmaceutical industry.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

22:13
Dakota Gold Corp Files for Common Stock Offering of up to $35.1 Mln - SEC Filing
22:11
Asiaray Media Group FY Ebitda RMB 593.2 Million
22:10
White House Source: We Expect to Have a Positive Announcement in the Near Future
22:10
White House Source: Talks Facilitated by the Trump Administration’s Technical Teams in Riyadh Are Going Extremely Well
22:10
EZCORP Inc - to Use $103.4 Mln of Proceeds to Repay Outstanding Notes

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1134814103?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2024-11-27 15:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134814103","market":"hk","top_or_hot":-1,"title":"Stock Track | WUXI XDC Soars 7.37% on Positive Analyst Coverage Initiation","media":"Stock Track","content":"<p>WUXI XDC, a leading biopharmaceutical company, saw its stock price surge 7.37% in intraday trading on Wednesday. The rally was driven by a bullish initiation of coverage from SPDB International HK.</p>\n\n<p>In a research note published on Wednesday afternoon, SPDB International HK analysts initiated coverage on WUXI XDC with a \"Buy\" rating and set a price target of HK$35 for the stock. The favorable outlook and positive rating triggered increased buying interest, propelling WUXI XDC's shares higher during the trading session.</p>\n\n<p>The surge in WUXI XDC's stock price highlights the market's reaction to the optimistic analyst coverage, underscoring investor confidence in the company's prospects and growth potential within the biopharmaceutical industry.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | WUXI XDC Soars 7.37% on Positive Analyst Coverage Initiation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | WUXI XDC Soars 7.37% on Positive Analyst Coverage Initiation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-27 15:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>WUXI XDC, a leading biopharmaceutical company, saw its stock price surge 7.37% in intraday trading on Wednesday. The rally was driven by a bullish initiation of coverage from SPDB International HK.</p>\n\n<p>In a research note published on Wednesday afternoon, SPDB International HK analysts initiated coverage on WUXI XDC with a \"Buy\" rating and set a price target of HK$35 for the stock. The favorable outlook and positive rating triggered increased buying interest, propelling WUXI XDC's shares higher during the trading session.</p>\n\n<p>The surge in WUXI XDC's stock price highlights the market's reaction to the optimistic analyst coverage, underscoring investor confidence in the company's prospects and growth potential within the biopharmaceutical industry.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02268","symbol_name":"药明合联","start_time":0,"source_url":"","article_id":"1134814103","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134814103","pubTimestamp":1732693474,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"WUXI XDC, a leading biopharmaceutical company, saw its stock price surge 7.37% in intraday trading on Wednesday. The rally was driven by a bullish initiation of coverage from SPDB International HK.In a research note published on Wednesday afternoon, SPDB International HK analysts initiated coverage on WUXI XDC with a \"Buy\" rating and set a price target of HK$35 for the stock. The favorable outlook and positive rating triggered increased buying interest, propelling WUXI XDC's shares higher during","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02268":"药明合联"},"translate_title":"股票赛道无锡XDC因分析师积极报道而飙升7.37%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02268":1},"content_text":"WUXI XDC, a leading biopharmaceutical company, saw its stock price surge 7.37% in intraday trading on Wednesday. The rally was driven by a bullish initiation of coverage from SPDB International HK.\nIn a research note published on Wednesday afternoon, SPDB International HK analysts initiated coverage on WUXI XDC with a \"Buy\" rating and set a price target of HK$35 for the stock. The favorable outlook and positive rating triggered increased buying interest, propelling WUXI XDC's shares higher during the trading session.\nThe surge in WUXI XDC's stock price highlights the market's reaction to the optimistic analyst coverage, underscoring investor confidence in the company's prospects and growth potential within the biopharmaceutical industry.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}